OptimizeRx (NASDAQ:OPRX) PT Lowered to $11.00 at Barclays

OptimizeRx (NASDAQ:OPRX) had its price objective cut by Barclays from $15.00 to $11.00 in a report released on Monday, Benzinga reports. They currently have an equal weight rating on the stock.

A number of other research analysts have also commented on the company. B. Riley assumed coverage on OptimizeRx in a report on Thursday, July 25th. They set a buy rating and a $18.50 price target for the company. JMP Securities reiterated a market outperform rating and set a $16.00 target price on shares of OptimizeRx in a research note on Friday, June 21st. Finally, Stifel Nicolaus restated a buy rating and issued a $13.00 price target on shares of OptimizeRx in a research report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $15.10.

OptimizeRx Stock Performance

OPRX traded up $0.07 during trading on Monday, hitting $8.47. The stock had a trading volume of 10,009 shares, compared to its average volume of 129,950. The company has a current ratio of 3.07, a quick ratio of 2.88 and a debt-to-equity ratio of 0.27. OptimizeRx has a 12 month low of $6.92 and a 12 month high of $16.65. The company has a 50 day simple moving average of $10.13 and a 200-day simple moving average of $11.80. The firm has a market cap of $154.75 million, a PE ratio of -8.24 and a beta of 1.26.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $19.69 million for the quarter, compared to analyst estimates of $18.66 million. OptimizeRx had a negative return on equity of 5.97% and a negative net margin of 21.53%. During the same period in the prior year, the firm posted ($0.34) EPS. Analysts expect that OptimizeRx will post -0.46 EPS for the current year.

Hedge Funds Weigh In On OptimizeRx

A number of hedge funds have recently made changes to their positions in OPRX. Summit Securities Group LLC bought a new stake in OptimizeRx in the second quarter valued at about $25,000. Nisa Investment Advisors LLC raised its stake in OptimizeRx by 215.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock worth $31,000 after acquiring an additional 1,462 shares in the last quarter. Cetera Trust Company N.A acquired a new stake in shares of OptimizeRx in the 4th quarter valued at $77,000. Connors Investor Services Inc. grew its holdings in shares of OptimizeRx by 15.1% in the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Hillsdale Investment Management Inc. acquired a new stake in shares of OptimizeRx during the 4th quarter worth about $225,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.